OPR - Delayed Quote • USD PLRX Jul 2024 20.000 call (PLRX240719C00020000) Follow 1.4000 0.0000 (0.00%) At close: March 13 at 9:30 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for PLRX240719C00020000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: PLRX Pliant Therapeutics to Participate in Upcoming Investor Events Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results Pliant Therapeutics to Participate in Upcoming Investor Conferences Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?
